🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501HIV Infection
Merck Sharp & Dohme LLC
Phase 3
641
East Sussex, Bristol, London, Crumpsall
2023-03-17
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Gilead Sciences
Phase 2
192
Birmingham, Leeds, London
2023-03-16
Recruiting
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
NCT05776069Von Willebrand Diseases
Vega Therapeutics, Inc
Phase 1/2
116
Birmingham, Southampton, London, Whitechapel
2023-03-16
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
London, Sheffield
2023-03-16
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
Pyxis Oncology, Inc
Phase 1
330
London
2023-03-14
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
537
Bristol, London, Manchester
2023-03-08
Active, closed
Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder
NCT05818943GRIN-related Disorders
GRIN Therapeutics, Inc.
Phase 1
24
Glasgow, London
2023-03-07
Active, closed
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca
Phase 2
188
London, Nottingham
2023-03-06
Recruiting
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971Alpha1-Antitrypsin Deficiency
Takeda
Phase 3
160
Cambridge, Edinburgh, London, Nottingham, Plymouth
2023-03-06
Active, closed
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399Melanoma
Bristol-Myers Squibb
Phase 3
579
London, Headington, Oxford, Newcastle upon Tyne
2023-03-06
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
Pfizer
Phase 3
624
London, Blackburn, Glasgow, Manchester
2023-03-03
Recruiting
Magseed Pro(R)/ Sentimag(R) Gen3
NCT05142787Breast Cancer
Endomagnetics Ltd.
Not applicable
224
London, Manchester
2023-03-02
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
NCT05797519Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
120
Brighton, London
2023-03-01
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 1/2
26
Cambridge, Glasgow, London, Manchester, Penarth, Southampton
2023-02-27
Recruiting
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
NCT05471856Solid Tumors
Boehringer Ingelheim
Phase 1
66
London, Oxford, Sutton
2023-02-24
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
London, Manchester, Sheffield, Southampton
2023-02-21
Active, closed
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931Advanced Non-Small Cell Lung Cancer
Gilead Sciences
Phase 2
400
London
2023-02-21
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Fore Biotherapeutics
Phase 2
254
Manchester, London
2023-02-21
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
553
East Sussex, Crumpsall, London, Newcastle upon Tyne, Birmingham
2023-02-20
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Active, closed
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940Treatment Resistant Depression
COMPASS Pathways
Phase 3
572
Bodmin, Chertsey, Chester, Doncaster, Exeter, Fulbourn, London, Newcastle
2023-02-14
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
London, Oxford
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Belfast, Cardiff, London, Sheffield
2023-02-13
Recruiting
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
NCT05660642Treatment Resistant Depression
Beckley Psytech Limited
Phase 2
72
Liverpool, London
2023-02-10
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT05496998Mitral Regurgitation
Medtronic Cardiovascular
Not applicable
400
Brighton, Leeds, London
2023-02-07
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
Belfast, Bradford, Frimley, Gloucester, Liverpool, London, Manchester, Newcastle
2023-02-07
Active, closed
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
NCT05548556Facioscapulohumeral Muscular Dystrophy (FSHD)
Hoffmann-La Roche
Phase 2
51
London, Newcastle upon Tyne
2023-02-07
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Birmingham, London, Nottingham
2023-02-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
London, Oxford
2023-02-02
Active, closed
Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness
NCT05362370Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Stryker Craniomaxillofacial
Observational
99
London
2023-02-01
Recruiting
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics
Observational
200
Glasgow, London
2023-01-31
Active, closed
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
NCT05701774Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Phase 3
83
Cambridge, Glasgow, Hull, London
2023-01-31
Active, closed
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Areteia Therapeutics
Phase 3
600
Bellshill, Birmingham, Bollington, Chorley, Enfield, Liverpool, London, Manchester
2023-01-30
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Sheffield, London, Middlesbrough, Wolverhampton, Cambridge
2023-01-25
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1/2
435
Liverpool, London
2023-01-24
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Recruiting
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
20
London
2023-01-23
Recruiting
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
NCT05587712Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 2
42
London
2023-01-19
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Abivax S.A.
Phase 3
1,116
Cambridge, London, Bury, Harrow, Yeovil, Huddersfield
2023-01-16
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 2
95
London, Manchester
2023-01-12
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
Bristol-Myers Squibb
Phase 3
513
London, Central Middlesbrough, Oxford
2023-01-12
Recruiting
OSTEOMICS: Identifying Regulators of Bone Homeostasis
NCT05732870Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
Relation Therapeutics
Observational
2,000
London
2023-01-12
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
1,170
London
2023-01-11
Active, closed
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013Crohn Disease, Colitis, Ulcerative
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
London
2023-01-11
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Ellipses Pharma
Phase 1/2
95
London, Manchester, Liverpool
2023-01-11
Active, closed
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560Mitral Stenosis, Mitral Valve Insufficiency
Edwards Lifesciences
Observational
504
Cambridge, London
2023-01-11
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
London, Newcastle upon Tyne, Oxford
2023-01-06
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
284
Nottingham, Cannock, London, Manchester, Newcastle upon Tyne
2023-01-02
By invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
NCT05768386Hemophilia A
BioMarin Pharmaceutical
Observational
172
Cambridge, Glasgow, London, Oxford, Southampton
2023-01-01
Active, closed
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673Non-Clear Cell Renal Cell Carcinoma
Exelixis
Phase 3
317
Sheffield, London
2023-01-01
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Birmingham, Leeds, London
2022-12-30
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Active, closed
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362Primary Sclerosing Cholangitis
Ipsen
Phase 2
68
Aberdeen, Birmingham, Frimley, Glasgow, Hull, London
2022-12-29
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
Pharvaris Netherlands B.V.
Phase 2/3
150
London
2022-12-28
Active, closed
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526Alzheimer Disease
AriBio Co., Ltd.
Phase 3
1,535
Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton
2022-12-23
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Active, closed
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Phase 3
20
London, Newcastle upon Tyne
2022-12-19
Recruiting
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
NCT05669950Congenital Adrenal Hyperplasia
H. Lundbeck A/S
Phase 1/2
42
Birmingham, Cambridge, London
2022-12-19
Active, closed
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459Amyotrophic Lateral Sclerosis
QurAlis Corporation
Phase 1
69
Sheffield, London
2022-12-16
Recruiting
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
NCT03994471End Stage Renal Disease
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Recruiting
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT05650229Primary Mitochondrial Disease
Pharming Technologies B.V.
Phase 2
180
Cambridge, London, Newcastle
2022-12-13
Active, closed
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
NCT06211634Glanzmann Thrombasthenia
Hemab ApS
Phase 1/2
57
Birmingham, Leeds, London, Whitechapel
2022-12-13
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
Gilead Sciences
Phase 3
1,514
Cottingham, Edgbaston, Liverpool, London, Manchester, Northwood, Taunton, York
2022-12-12
Active, closed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316Advanced Melanoma
Agenus Inc.
Phase 2
150
London, Manchester, Middlesex
2022-12-12
Active, closed
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
NCT05677763Respiratory Tract Infections, Wheezing Lower Respiratory Illness
OM Pharma SA
Phase 4
525
Brighton, Manchester, Nottingham, Edinburgh, London
2022-12-12
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
Pfizer
Phase 3
100
Newcastle upon Tyne, Birmingham, London, Manchester
2022-12-09
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
By invitation
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
NCT05492799MPS III B
Allievex Corporation
Phase 4
15
London
2022-12-02
Recruiting
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
NCT05652439Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A.
Observational
25,000
London
2022-12-02
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Bellshill, Edgbaston, Manchester, Cardiff, Hampstead, Liverpool, London
2022-11-30
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Immunophotonics, Inc.
Phase 1/2
42
London, Oxford
2022-11-29
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Cambridge, London, Warrington
2022-11-25
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Phase 3
568
Glasgow, Gloucester, London, Newport
2022-11-21
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Liverpool, London, Oxford, Sheffield
2022-11-21
Recruiting
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT05562830Urothelial Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
48
London
2022-11-16
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
London
2022-11-10
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
Bayer
Phase 3
100
London, Manchester, Nottingham, Glasgow
2022-11-08
Active, closed
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446Myelodysplastic Syndromes
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Active, closed
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
NCT05608876Head and Neck Cancer
QBiotics Group Limited
Phase 2
15
Cardiff, Stevenage, Bebington, London
2022-11-03
Active, closed
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc.
Phase 3
80
Airdrie, Leeds, London
2022-10-28
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05169515Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Sotio Biotech Inc.
Phase 1/2
7
Glasgow, London
2022-10-26
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
136
Cambridge, London
2022-10-25
Rows per page Showing 1201–1300 of 2005
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=13

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.